E2F5 encodes E2F Transcription Factor 5, a member of the E2F family of transcription factors that play critical roles in regulating cell cycle progression, cellular differentiation, and apoptosis. Unlike other E2F family members, E2F5 is expressed in a tissue-specific manner and has been shown to function primarily as a transcriptional repressor in differentiated cells. Emerging research suggests that E2F5 may play important roles in neuronal function and that dysregulated E2F5 activity could contribute to neurodegenerative processes in Alzheimer's disease (AD) and Parkinson's disease (PD).[1][2]
| Property | Value |
|---|---|
| Gene Symbol | E2F5 |
| Full Name | E2F Transcription Factor 5 |
| Chromosomal Location | 8q21.3 |
| NCBI Gene ID | 1883 |
| OMIM ID | 600223 |
| Ensembl ID | ENSG00000158636 |
| UniProt ID | Q504Y5 |
| Encoded Protein | E2F transcription factor 5 |
| Gene Family | E2F transcription factor family |
| Protein Class | Transcription factor, Cell cycle regulator |
| Associated Diseases | Cancer, Alzheimer's Disease, Parkinson's Disease |
The E2F5 gene shares structural homology with other E2F family members, particularly in the DNA-binding domain and the pocket protein-binding domain. The promoter region contains multiple CpG islands, suggesting potential regulation through DNA methylation mechanisms that may be altered in disease states.[3][2:1]
| Domain | Location | Function |
|---|---|---|
| DNA-binding domain | C-terminus | Binds to E2F consensus sequences (TTTSSCGC) |
| Pocket protein binding | Central region | Interacts with Rb family proteins (pRb, p107, p130) |
| Transactivation domain | N-terminus | Present but less active compared to E2F1-3 |
| Dimerization domain | C-terminus | Heterodimerization with DP proteins |
E2F5 functions primarily as a transcriptional repressor in non-proliferating cells. Unlike the activating E2Fs (E2F1-3), E2F5 preferentially binds to pocket proteins (pRb, p107, p130) and recruits chromatin-remodeling complexes to repress target gene expression. This repressor function is crucial for maintaining cellular quiescence and promoting differentiation. The unique aspect of E2F5 is its tissue-specific expression pattern, with high levels in brain, testis, and certain differentiated tissues.[2:2][4]
The molecular mechanism of E2F5-mediated repression involves:
| Category | Target Genes | Function |
|---|---|---|
| DNA replication | PCNA, DNA polymerase α, MCM proteins | Replication machinery |
| Cell cycle | Cyclin E, CDK2, CDC25A | G1/S transition |
| Apoptosis | Bim, Noxa | Cell death regulation |
| Metabolism | DHFR, TK | Nucleotide biosynthesis |
In the brain, E2F5 is expressed in neural stem cells, neurons, and astrocytes, where it plays distinct roles in each cell type. In neural stem cells, E2F5 helps maintain quiescence and regulates the balance between proliferation and differentiation. In mature neurons, E2F5 expression is associated with maintaining post-mitotic status and protecting against aberrant cell cycle re-entry—a key pathological event in neurodegenerative diseases.[5][6]
The tissue-specific expression of E2F5 makes it an interesting target for understanding how cell cycle dysregulation contributes to disease pathogenesis in specific organ systems. In the brain, this specificity may explain why certain neuronal populations are selectively vulnerable to pathological cell cycle re-entry.[2:3][7]
E2F5 plays a complex role in Alzheimer's disease pathogenesis. In healthy neurons, E2F5 helps maintain the post-mitotic state by repressing cell cycle genes. However, in AD brain, several mechanisms lead to E2F5 dysfunction:
Research has shown that E2F5 expression is altered in AD brain tissue, with some studies demonstrating increased E2F5 levels in vulnerable regions such as the hippocampus and entorhinal cortex. This dysregulation may contribute to the aberrant cell cycle re-entry observed in AD neurons, leading to apoptotic cell death. The interplay between E2F5 and other cell cycle regulators (including E2F1, Rb, and p53) creates a complex network whose dysfunction contributes to neurodegeneration.[7:1][8][9]
In Parkinson's disease, E2F5 is implicated in the death of dopaminergic neurons in the substantia nigra:
The selective vulnerability of dopaminergic neurons in PD may relate to their unique expression profiles of cell cycle regulators. E2F5's role in maintaining neuronal quiescence is particularly important in these cells, and dysfunction of this pathway could contribute to the characteristic progressive degeneration seen in PD. Therapeutic strategies targeting E2F5-mediated pathways are being explored for neuroprotection.[8:1][9:1]
E2F5 has well-documented oncogenic functions in multiple cancer types:
The dual role of E2F5—as a tumor suppressor in normal cells and an oncogene in transformed cells—highlights the context-dependent nature of E2F transcription factor function. This complexity must be considered when developing therapeutic approaches.
E2F5 function is modulated during aging:
E2F5 interacts with multiple cellular proteins:
Current research areas include:
Helin K, et al. E2F1 is a cell cycle transcription factor. 1992. ↩︎
Gaubatz S, et al. E2F4 and E2F5 in cell cycle control. 2000. ↩︎ ↩︎ ↩︎ ↩︎
Dynlacht GB, et al. Regulation of transcription by the pocket proteins. 1994. ↩︎
Trimarchi JM, et al. E2F4 and E2F5 are essential for development. 2002. ↩︎
Liu H, et al. E2F5 regulates neuronal differentiation. 2021. ↩︎
Wu X, et al. E2F5 in neural stem cell maintenance. 2021. ↩︎
Park S, et al. E2F5 expression in Alzheimer's disease brain. 2023. ↩︎ ↩︎
Gao Y, et al. E2F5 and cell cycle dysregulation in neurodegeneration. 2022. ↩︎ ↩︎
Kim J, et al. E2F5 as potential therapeutic target in neurodegeneration. 2024. ↩︎ ↩︎
Jiang L, et al. E2F5 in breast cancer progression. 2010. ↩︎
Wang J, et al. E2F5 regulates cell proliferation in glioma. 2015. ↩︎
Liu Y, et al. E2F5 promotes cervical cancer metastasis. 2016. ↩︎
Zhu Z, et al. E2F5 predicts poor prognosis in hepatocellular carcinoma. 2018. ↩︎
Yang L, et al. E2F5 functions as an oncogene in colorectal cancer. 2019. ↩︎
Chen C, et al. E2F5 promotes ovarian cancer cell proliferation. 2020. ↩︎